


## CEBPA Mutation by PCR

Order Name: **CEBPA PCR**  
Test Number: 9616990  
Revision Date: 01/24/2025

TEST NAME	METHODOLOGY	LOINC CODE
CEBPA Mutation by PCR	<u>Polymerase Chain Reaction</u>	

SPECIMEN REQUIREMENTS				
Specimen	Specimen Volume (min)	Specimen Type	Specimen Container	Transport Environment
Preferred	5 mL (3 mL)	Whole Blood	EDTA (Lavender Top)	Room Temperature
Alternate 1	5 mL (3 mL)	Whole Blood	Sodium Heparin (Green Top / No-Gel)	Room Temperature
Alternate 2	2 mL (1 mL)	Bone Marrow	EDTA (Lavender Top)	Room Temperature
Alternate 3	2mL (1mL)	Bone Marrow	Sodium Heparin (Green Top / No-Gel)	Room Temperature
Instructions	<p><b>Specimen:</b> 5mL(3mL) Whole Blood or 2mL (1mL) Bone Marrow</p> <p><b>Container:</b> Lavender-top (EDTA) tube, green-top (sodium heparin) tube</p> <p><b>Collection:</b> Indicate date and time of collection on the test request form. Submit specimen at room temperature ASAP, Keep at room temperature! (DO NOT FREEZE). Frozen samples will be rejected.</p> <p><b>Storage Instructions:</b> Maintain specimen at room temperature. If specimen is to be stored prior to shipment, store at 2°C to 8°C.</p> <p><b>Cause for Rejection:</b> Specimen does not meet all of the above criteria for sample type, container, minimum volume, collection and storage; unsuitable specimens include but are not limited to: frozen whole blood or marrow; a leaking tube; clotted blood or marrow; a grossly hemolyzed specimen or otherwise visibly degraded; specimen suspected of being contaminated by another specimen; specimen contains specific foreign material.</p>			

GENERAL INFORMATION	
Testing Schedule	Mon- Fri
Expected TAT	12-14 Days from set up.
Clinical Use	<p>Determine prognosis in cytogenetically normal acute myelogenous leukemia (CN-AML)</p> <p>The CEBPA (CCAAT/enhancer binding protein ) gene encodes a transcription factor important for granulocyte differentiation. CEBPA mutations are found in 6% to 15% of de novo acute myeloid leukemia (AML) and in 15% to 18% of AML with normal karyotypes. CEBPA mutations are associated with favorable prognosis in the absence of associated cytogenetic abnormalities and FLT3 internal duplication (FLT3-ITD). Germline CEBPA mutations are a cause of nonsyndromic, familial AML.</p>
CPT Code(s)	81218
Service Provided By	 <b>labcorp</b> Oklahoma, Inc.